CoChat

The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone

Open access

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

BACKGROUND. Liraglutide leading to improve not only glycaemic control but also liver inflammation in non-alcoholic fatty liver disease (NAFLD) patients. AIMS. The aim of this study is to elucidate the effectiveness of liraglutide in NAFLD patients with type 2 diabetes mellitus (T2DM) compared to sitagliptin and pioglitazone. METHODS. We retrospectively enrolled 82 Japanese NAFLD patients with T2DM and divided into three groups (liraglutide: N = 26, sitagliptin; N = 36, pioglitazone; N = 20). We compared the baseline characteristics, changes of laboratory data and body weight. RESULTS. At the end of follow-up, ALT, fast blood glucose, and HbA1c level significantly improved among the three groups. AST to platelet ratio significantly decreased in liraglutide group and pioglitazone group. The body weight significantly decreased in liraglutide group (81.8 kg to 78.0 kg, P < 0.01). On the other hands, the body weight significantly increased in pioglitazone group and did not change in sitagliptin group. Multivariate regression analysis indicated that administration of liraglutide as an independent factor of body weight reduction for more than 5% (OR 9.04; 95% CI 1.12-73.1, P = 0.04). CONCLUSIONS. Administration of liraglutide improved T2DM but also improvement of liver inflammation, alteration of liver fibrosis, and reduction of body weight.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1100/2012/496453

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 A total of 126 patients who were clinically diagnosed NAFLD with type 2 DM visited the outpatient clinic of Department of Diabetes and Metabolism or Department of Gastroenterology, Mitsui Memorial Hospital. We retrospectively analyzed 82 of them, excluding 44 patients only treated with insulin injection or exercise and diet therapy. We divided the rest 82 patients into three groups: liraglutide-treated group (N = 26), sitagliptin-treated group (N = 36), and pioglitazone-treated group (N = 20).
Figure 1 A total of 126 patients who were clinically diagnosed NAFLD with type 2 DM visited the outpatient clinic of Department of Diabetes and Metabolism or Department of Gastroenterology, Mitsui Memorial Hospital. We retrospectively analyzed 82 of them, excluding 44 patients only treated with insulin injection or exercise and diet therapy. We divided the rest 82 patients into three groups: liraglutide-treated group (N = 26), sitagliptin-treated group (N = 36), and pioglitazone-treated group (N = 20).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Research works printed but not linked: 2

  1. 10.1111/j.1572-0241.2003.07486.x · doi:10.1111/j.1572-0241.2003.07486.x · Paper page
  2. 10.1053/jhep.2003.50420 · doi:10.1053/jhep.2003.50420 · Paper page

Cited by

See all 147

Metadata

Authors
Ohki, T., Isogawa, A., Iwamoto, M., Ohsugi, M., Yoshida, H., Toda, N., Tagawa, K., Omata, M., & Koike, K.
Affiliations
  • Mitsui Memorial Hospital (JP)
  • The University of Tokyo (JP)
  • Yamanashi Prefectural Hospital Organization (JP)
Corresponding author
Yoshida, Haruhiko
Venue
The Scientific World Journal
Publisher
Wiley
Published
2012
Volume
2012
Pages
1-8
ISSN
1537-744X (ISSN-L)
OpenAlex
W2113064802
Cited by
139
References
29
Citations by year
2026: 4 · 2025: 5 · 2024: 14 · 2023: 11 · 2022: 10 · 2021: 15 · 2020: 15 · 2019: 11 · 2018: 11 · 2017: 6 · 2016: 14 · 2015: 10 · 2014: 9 · 2013: 3
FWCI
5.65
Type
journal article
Language
en
Open access
Locations
  • The Scientific World JOURNAL (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
liraglutide, non-alcoholic fatty liver disease, type 2 diabetes, sitagliptin, pioglitazone, weight loss, liver inflammation, ALT, HbA1c, glycemic control, GLP-1 receptor agonists
MeSH terms
Sitagliptin Phosphate, Liraglutide, Pioglitazone, Adult, Alanine Transaminase, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Drug Evaluation, Drug Therapy, Combination, Fatty Liver, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Inflammation, Liver Cirrhosis, Male, Middle Aged, Platelet Count, Pyrazines, Retrospective Studies, Triazoles, Comorbidity, Multivariate Analysis, Logistic Models, Odds Ratio, Treatment Outcome, Thiazolidinediones, Glucagon-Like Peptide 1, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone. https://app.cochat.ai/papers/10.1100/2012/496453
The paper
Ohki, T., Isogawa, A., Iwamoto, M., Ohsugi, M., Yoshida, H., Toda, N., Tagawa, K., Omata, M., & Koike, K. (2012). The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone. The Scientific World Journal. https://doi.org/10.1100/2012/496453

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.